Skip to main navigation
Skip to content
Skip to primary sidebar
Skip to footer
240.243.1201
info@glycomimetics.com
Careers
Contact Us
Investor Relations
About Us
About Us
Board of Directors
Management Team
Core Values
Patients
Clinical Trials
Expanded Access
Pipeline
Pipeline Overview
Uproleselan
GMI-1687
Galectin Antagonists
AML & E-selectin
Understanding Glycobiology
Science
Scientific Publications
Intellectual Property
Platform & Research
Collaborations
Investors
Investors
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports & Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Ownership Profile
Contact Us
Event Details
Investor Relations
About Us
About Us
Board of Directors
Management Team
Core Values
Patients
Clinical Trials
Expanded Access
Pipeline
Pipeline Overview
Uproleselan
GMI-1687
Galectin Antagonists
AML & E-selectin
Understanding Glycobiology
Science
Scientific Publications
Intellectual Property
Platform & Research
Collaborations
Investors
Investors
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports & Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Ownership Profile
Contact Us
Events & Presentations
GlycoMimetics Corporate Update Call
May 6, 2024 8:30 AM EDT
Listen to webcast
Shareholder Tools
Print
Print
Printed Materials
Printed Materials
Email Alerts
Email Alerts
RSS
RSS
Search
Search
